Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
KALV
$15.85
$
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Next Earnings
2026-02-25
Beta
-0.347
Average Volume
Market Cap
Last Dividend
CIK
0001348911
ISIN
US4834971032
CUSIP
483497103
CEO
Benjamin L. Palleiko
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
150
IPO Date
2015-04-09
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| KalVista Pharmaceuticals to Present at Upcoming Investor Conferences | FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at each of the following upcoming investor conferences: TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026, at 11:10 a.m. EST The Citizens Life Sciences Conference on Wednesday, March 11, 2026, at 10:45 a.m. EST The live audio webcast of each presentation will be accessible on the Investors section of the. | Business Wire | 2026-02-25 07:00:00 |
| Wall Street Analysts Think KalVista Pharmaceuticals (KALV) Could Surge 117.1%: Read This Before Placing a Bet | The consensus price target hints at an 117.1% upside potential for KalVista Pharmaceuticals (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. | Zacks Investment Research | 2026-02-24 10:55:41 |
| KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline | FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the newly published International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary Angioedema recommends EKTERLY® (sebetralstat) as a first-line therapy for the acute treatment of hereditary angioedema (HAE) attacks in adolescents aged 12 years and older.1 Based on robust, high-quality evidence, including clinical trial data demonstrating con. | Business Wire | 2026-02-18 07:00:00 |
| Financial Survey: SCYNEXIS (NASDAQ:SCYX) and KalVista Pharmaceuticals (NASDAQ:KALV) | KalVista Pharmaceuticals (NASDAQ: KALV - Get Free Report) and SCYNEXIS (NASDAQ: SCYX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends. Valuation and Earnings This table compares KalVista Pharmaceuticals | Defense World | 2026-02-16 01:58:55 |
| KalVista Pharmaceuticals to Present EKTERLY® (sebetralstat) Data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting | FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of three abstracts for presentation at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Philadelphia, Pennsylvania from February 27–March 2, 2026. The following poster presentations will take place on Friday, February 27 from 2:45–3:45 pm ET in the Convention Center, Level 2, Hall E: Response Drivers in Sebetral. | Business Wire | 2026-02-12 07:00:00 |
| KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion | KalVista Pharmaceuticals retains a 'Strong Buy' rating, driven by EKTERLY's global launch and robust initial sales momentum. Company achieved $35M in Q4 2025 and $49M in full-year 2025 unaudited EKTERLY revenues, with demand in Germany matching the U.S. launch trajectory. Key upside catalyst is the KONFIDENT-KID phase 3 trial, targeting label expansion for pediatric HAE patients ages 2–11, with NDA filing expected Q3 2026. | Seeking Alpha | 2026-02-11 15:39:33 |
| KalVista Pharmaceuticals (NASDAQ:KALV) vs. Enanta Pharmaceuticals (NASDAQ:ENTA) Financial Review | KalVista Pharmaceuticals (NASDAQ: KALV - Get Free Report) and Enanta Pharmaceuticals (NASDAQ: ENTA - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings. Insider and Institutional Ownership 95.0% of Enanta | Defense World | 2026-02-05 01:34:46 |
| KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted six newly-hired employees inducement options to purchase an aggregate of 96,750 shares of KalVista common stock on February 1, 2026 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stoc. | Business Wire | 2026-02-03 07:00:00 |
| Wall Street Analysts Believe KalVista Pharmaceuticals (KALV) Could Rally 116.4%: Here's is How to Trade | The consensus price target hints at an 116.4% upside potential for KalVista Pharmaceuticals (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. | Zacks Investment Research | 2026-02-02 10:55:36 |
| Emerald Advisers LLC Grows Position in KalVista Pharmaceuticals, Inc. $KALV | Emerald Advisers LLC raised its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) by 30.2% during the third quarter, according to its most recent filing with the SEC. The firm owned 1,351,254 shares of the specialty pharmaceutical company's stock after purchasing an additional 313,205 shares during the period. Emerald Advisers LLC owned | Defense World | 2026-01-22 04:53:00 |
| KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of “Moderate Buy” from Brokerages | KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report) has been given an average rating of "Moderate Buy" by the nine research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The average | Defense World | 2026-01-16 01:22:48 |
| Does KalVista Pharmaceuticals (KALV) Have the Potential to Rally 117.98% as Wall Street Analysts Expect? | The mean of analysts' price targets for KalVista Pharmaceuticals (KALV) points to an 118% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. | Zacks Investment Research | 2026-01-15 10:56:02 |
| KalVista Details Early Sales, Prescriber Uptake For Newly Approved Rare Swelling Drug | KalVista Pharmaceuticals Inc. (NASDAQ: KALV) on Thursday reported early commercial momentum for its hereditary angioedema treatment EKTERLY, highlighting growing prescriber adoption, repeat prescriptions and expanding global access following its mid-2025 launch. | Benzinga | 2026-01-09 09:56:10 |
| Stock Market Today: Nasdaq 100, S&P 500 Futures Gain As Investors Await December Jobs Report— General Motors, Offerpad, Tilray In Focus | U.S. stock futures pared earlier losses to advance on Friday after a mixed Thursday. Futures of major benchmark indices were trading higher. | Benzinga | 2026-01-09 05:43:41 |
| KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results | FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided its preliminary fourth quarter and full year ended December 31, 2025 unaudited global net product revenue results and other operational indicators. “We are extremely pleased with our performance since launching EKTERLY in July, which reflects steady execution, growing utilization, and continued momentum across our business,” said Ben Palleiko, CEO of KalVista. “Fundamental dema. | Business Wire | 2026-01-08 16:05:00 |
| KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema | FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing approval for EKTERLY® (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. EKTERLY is the first and only oral on-demand treatment for HAE approved in Japan. EKT. | Business Wire | 2025-12-22 06:00:00 |
| KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Rating of “Moderate Buy” by Analysts | KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and nine have given a buy recommendation to the company. The average twelve-month price target | Defense World | 2025-12-22 01:11:02 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-24 | 2026-02-24 | View Filing |
| 4 | 2026-02-19 | 2026-02-19 | View Filing |
| 4 | 2026-02-19 | 2026-02-19 | View Filing |
| 4 | 2026-02-19 | 2026-02-19 | View Filing |
| 4 | 2026-02-13 | 2026-02-13 | View Filing |
| S-8 | 2026-01-26 | 2026-01-26 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| 4 | 2026-01-21 | 2026-01-21 | View Filing |
| SC 13G/A | 2026-01-13 | 2026-01-13 | View Filing |
| SC 13G | 2026-01-12 | 2026-01-12 | View Filing |
| 8-K | 2026-01-08 | 2026-01-08 | View Filing |
| SC 13G/A | 2025-12-30 | 2025-12-30 | View Filing |
| 4 | 2025-12-09 | 2025-12-09 | View Filing |
| 4 | 2025-12-04 | 2025-12-04 | View Filing |
| 4 | 2025-11-26 | 2025-11-26 | View Filing |
| 4 | 2025-11-26 | 2025-11-26 | View Filing |
| 4 | 2025-11-26 | 2025-11-26 | View Filing |
| 4 | 2025-11-26 | 2025-11-26 | View Filing |
| 4 | 2025-11-21 | 2025-11-21 | View Filing |
| 4 | 2025-11-19 | 2025-11-19 | View Filing |
| 4 | 2025-11-19 | 2025-11-19 | View Filing |
| 4 | 2025-11-19 | 2025-11-19 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| 4 | 2025-11-13 | 2025-11-13 | View Filing |
| 10-Q | 2025-11-10 | 2025-11-10 | View Filing |
| 8-K | 2025-11-10 | 2025-11-10 | View Filing |
| SC 13G | 2025-11-10 | 2025-11-10 | View Filing |
| SC 13D/A | 2025-11-04 | 2025-11-04 | View Filing |
| 4 | 2025-10-08 | 2025-10-08 | View Filing |
| 3 | 2025-10-08 | 2025-10-08 | View Filing |
| 8-K | 2025-10-06 | 2025-10-06 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 4 | 2025-10-02 | 2025-10-02 | View Filing |
| 3 | 2025-10-02 | 2025-10-02 | View Filing |
| 8-K | 2025-10-02 | 2025-10-02 | View Filing |
| 8-K | 2025-09-29 | 2025-09-29 | View Filing |
| 10-Q | 2025-09-11 | 2025-09-11 | View Filing |
| 8-K | 2025-09-11 | 2025-09-11 | View Filing |
| 4 | 2025-09-09 | 2025-09-09 | View Filing |
| 4 | 2025-08-26 | 2025-08-26 | View Filing |
| 4 | 2025-08-26 | 2025-08-26 | View Filing |
| 4 | 2025-08-26 | 2025-08-26 | View Filing |
| 4 | 2025-08-25 | 2025-08-25 | View Filing |
| 3 | 2025-08-25 | 2025-08-25 | View Filing |
| 4 | 2025-08-25 | 2025-08-25 | View Filing |
| 4 | 2025-08-25 | 2025-08-25 | View Filing |
| 4 | 2025-08-25 | 2025-08-25 | View Filing |
| 8-K | 2025-08-21 | 2025-08-21 | View Filing |
| ARS | 2025-08-21 | 2025-08-21 | View Filing |
| DEFA14A | 2025-08-21 | 2025-08-21 | View Filing |
| DEF 14A | 2025-08-21 | 2025-08-21 | View Filing |
| SC 13D/A | 2025-08-20 | 2025-08-20 | View Filing |
| 4 | 2025-08-19 | 2025-08-19 | View Filing |
| 4 | 2025-08-19 | 2025-08-19 | View Filing |
| 4 | 2025-08-19 | 2025-08-19 | View Filing |
| 4 | 2025-08-13 | 2025-08-13 | View Filing |
| 4 | 2025-07-10 | 2025-07-10 | View Filing |
| 4 | 2025-07-10 | 2025-07-10 | View Filing |
| 424B5 | 2025-07-10 | 2025-07-10 | View Filing |
| 10-K | 2025-07-10 | 2025-07-10 | View Filing |
| 8-K | 2025-07-10 | 2025-07-10 | View Filing |
| 8-K | 2025-07-07 | 2025-07-07 | View Filing |
| 4 | 2025-06-10 | 2025-06-10 | View Filing |
| 4 | 2025-05-27 | 2025-05-27 | View Filing |
| 4 | 2025-05-27 | 2025-05-27 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-23 | 2025-05-23 | View Filing |
| 4 | 2025-05-20 | 2025-05-20 | View Filing |
| 4 | 2025-05-20 | 2025-05-20 | View Filing |
| 4 | 2025-05-20 | 2025-05-20 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G/A | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-12 | 2025-05-12 | View Filing |
| 4 | 2025-04-11 | 2025-04-11 | View Filing |
| 8-K | 2025-04-08 | 2025-04-08 | View Filing |
| 8-K | 2025-03-17 | 2025-03-17 | View Filing |
| 8-K | 2025-03-12 | 2025-03-12 | View Filing |
| 10-Q | 2025-03-12 | 2025-03-12 | View Filing |
| 4 | 2025-03-10 | 2025-03-10 | View Filing |
| 4 | 2025-02-25 | 2025-02-25 | View Filing |
| 4 | 2025-02-25 | 2025-02-25 | View Filing |
| 4 | 2025-02-25 | 2025-02-25 | View Filing |
| 4 | 2025-02-25 | 2025-02-25 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-02-11 | 2025-02-11 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Keltner Channel Strategy | 238.59% | 0.28 | 36 | 0.42 | 0 | 135.3 |
| Turtle Trading Strategy | 205.51% | 0.6 | 6 | 0.58 | 1.28 | 102.21 |
| Triple MA | 200.55% | 0.84 | 18 | 0.62 | 4.48 | 97.25 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxx | xxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxx% | xxxx | x | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxx | xxxxx% | x | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | x | xxxxx | xxxxx | xxxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxxx |